WallStSmart
ARGX

argenx NV ADR

NASDAQ: ARGX · HEALTHCARE · BIOTECHNOLOGY

$782.17
+5.82% today

Updated 2026-06-05

Market cap
$55.09B
P/E ratio
39.11
P/S ratio
11.62x
EPS (TTM)
$22.54
Dividend yield
52W range
$510 – $935
Volume
0.3M

WallStSmart proprietary scores

73
out of 100
Grade: B
Buy
Investment rating
10.0
Growth
A+
8.5
Quality
A
9.5
Profitability
A+
6.7
Valuation
B
3/9
Piotroski F-Score
Weak
4.9
Altman Z-Score
Safe zone
Industry rank
View all highly rated stocks (75+) →199 stocks currently score above 75

Price targets

Analyst target
$1,018.00
+30.15%
12-Month target
$585.53
-25.14%
Intrinsic (DCF)
$2,217.64
Margin of safety
+62.37%
6 Strong Buy15 Buy3 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths
+ Altman Z 4.92 — safe zone
+ Profit margin 31.40% — above average
+ ROE 27.36% — strong efficiency
+ Revenue growth 62.60% QoQ
+ 62.37% below intrinsic value
Risks
- Piotroski 3/9 — weak financial health

Key financials

Revenue Net Income Free Cash Flow
Metric2022202320242025TTM2026 (E)
Revenue$410.75M$1.23B$2.19B$4.15B$4.74B$6.1B
Net income$-709.59M$-295.05M$833.04M$1.29B$366.00M
EPS$22.54$27.11
Free cash flow$-966.63M$-464.14M$-151.05M$844.30M
Profit margin-172.76%-24.06%38.03%31.11%31.40%

Peer comparison

CompanyMkt CapScoreGrowthProfitValueQualityMoSRating
ARGX$55.09B7310.09.56.78.5+62.37%Strong Buy
LLY$948.95B7810.010.05.06.0Strong Buy
JNJ$536.54B594.79.03.36.0-71.41%Buy
ABBV$380.57B634.08.04.05.0-55.64%Buy
UNH$343.21B545.35.54.75.5-26.61%Buy
MRK$285.64B503.38.02.75.0-49.34%Hold

Smart narrative

argenx NV ADR trades at $782.17. representing a P/E of 39.11x trailing earnings. Our Smart Value Score of 73/100 indicates the stock is good. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 4.92, it sits in the safe zone. TTM revenue stands at $4.74B. with profit margins at 31.40%. Our DCF model estimates intrinsic value at $2,217.64.

Frequently asked questions

What is argenx NV ADR's stock price?

argenx NV ADR (ARGX) trades at $782.17, on a P/E of 39.1x and a P/S of 11.6x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.

Is argenx NV ADR overvalued?

argenx NV ADR carries a Smart Value Score of 73/100 (Grade B), which we rate Buy. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $2,217.64 versus the $782.17 price, a 62.4% margin of safety on a cash flow basis.

What is the price target of argenx NV ADR (ARGX)?

The 12-month analyst consensus target is $1,018.00, about 30.2% above the current $782.17. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

What is the future stock price of ARGX by 2030?

Our research-backed model puts the 2030 base case at $1,175.66, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.

What is the intrinsic value of argenx NV ADR (ARGX)?

Our DCF model estimates intrinsic value at $2,217.64, a +62.4% margin of safety versus today's $782.17. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.

What is argenx NV ADR's revenue?

argenx NV ADR's trailing twelve-month revenue is $4.74B, and our model projects it reaching about $17.20B by 2030. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.

Altman Z-Score?

argenx NV ADR's Altman Z-Score is 4.92, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD

Quick metrics

P/S ratio11.62x
ROE27.36%
Beta-0.03
50D MA$799.53
200D MA$803.63
Shares out0.06B
Float1.55B
Short ratio
Avg volume0.3M

Performance

1 week+0.00%
1 month+11.51%
3 months+26.73%
YTD+5.99%
1 year
3 years
5 years